GSK Infectious Disease Deal History & Licensing Activity
GSK Infectious Disease is a large pharma headquartered in UK. Over the past three years, GSK Infectious Disease has been involved in 12 licensing and acquisition transactions, with a primary focus on Small Molecules (7 deals). The company currently has 5 active clinical trials, primarily in Oncology.
Deals (12mo)
6
Active Trials
5
Top Modality
Small Molecules
Focus Area
Oncology
GSK Infectious Disease Recent Deal Activity
Licensing, acquisition, and partnership transactions involving GSK Infectious Disease in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| bepirovirsen | GSK | Oligonucleotides | Approved | collaboration | Jul 28, 2026 |
| Nuvalent oncology pipeline | GSK | Small Molecules | Unknown | acquisition | Jul 1, 2026 |
| EOS-448 (belrestotug) | GSK | Antibodies | Phase 2 | co development | Jun 25, 2026 |
| Nuvalent pipeline (targeted kinase inhibitors for NSCLC) | GSK | Small Molecules | Unknown | acquisition | Jun 15, 2026 |
| linerixibat | Alfasigma S.p.A. | Small Molecules | Phase 3 | license | Apr 22, 2026 |
| HS235 | GSK | Small Molecules | Phase 1 | acquisition | Feb 25, 2026 |
| Undisclosed | GSK plc | Oligonucleotides | Unknown | license | Feb 25, 2026 |
GSK Infectious Disease Pipeline Focus
Therapeutic areas and modalities where GSK Infectious Disease is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
GSK Infectious Disease Strategic Signals
Key indicators of GSK Infectious Disease's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
GSK Infectious Disease Clinical Pipeline
GSK Infectious Disease has 5 active clinical trials across 3 development phases.
2
Phase 1
1
Phase 2
2
Phase 3
See How Your Asset Matches GSK Infectious Disease's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About GSK Infectious Disease Licensing & Deal Activity
GSK Infectious Disease is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 12 deals over the past three years, GSK Infectious Disease ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for GSK Infectious Disease include Oncology (5 deals and trials), Mega Deals (3 deals and trials), Infectious Disease (2 deals and trials), and Metabolic (2 deals and trials). In terms of modality, GSK Infectious Disease has shown particular interest in small molecules, oligonucleotides, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for GSK Infectious Disease and 700+ other biopharma companies. Use our Solidus to benchmark your asset against GSK Infectious Disease's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.